183 related articles for article (PubMed ID: 17630416)
1. Modeling of human dermal absorption of octamethylcyclotetrasiloxane (D(4)) and decamethylcyclopentasiloxane (D(5)).
Reddy MB; Looney RJ; Utell MJ; Plotzke KP; Andersen ME
Toxicol Sci; 2007 Oct; 99(2):422-31. PubMed ID: 17630416
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo percutaneous absorption of 14C-octamethylcyclotetrasiloxane (14C-D4) and 14C-decamethylcyclopentasiloxane (14C-D5).
Jovanovic ML; McMahon JM; McNett DA; Tobin JM; Plotzke KP
Regul Toxicol Pharmacol; 2008 Mar; 50(2):239-48. PubMed ID: 18178298
[TBL] [Abstract][Full Text] [Related]
3. Effect of PBPK model structure on interpretation of in vivo human aqueous dermal exposure trials.
Norman AM; Kissel JC; Shirai JH; Smith JA; Stumbaugh KL; Bunge AL
Toxicol Sci; 2008 Jul; 104(1):210-7. PubMed ID: 18381354
[TBL] [Abstract][Full Text] [Related]
4. Physiologically based modeling of nonsteady state dermal absorption of halogenated methanes from an aqueous solution.
Jepson GW; McDougal JN
Toxicol Appl Pharmacol; 1997 Jun; 144(2):315-24. PubMed ID: 9194415
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of aminomethylpropanol in rats following oral and a novel dermal study design.
Saghir SA; Clark AJ; McClymont EL; Staley JL
Food Chem Toxicol; 2008 Feb; 46(2):678-87. PubMed ID: 17961896
[TBL] [Abstract][Full Text] [Related]
6. Are highly lipophilic volatile compounds expected to bioaccumulate with repeated exposures?
Andersen ME; Reddy MB; Plotzke KP
Toxicol Lett; 2008 Jun; 179(2):85-92. PubMed ID: 18513896
[TBL] [Abstract][Full Text] [Related]
7. Aggregate dermal exposure to cyclic siloxanes in personal care products: implications for risk assessment.
Biesterbos JW; Beckmann G; van Wel L; Anzion RB; von Goetz N; Dudzina T; Roeleveld N; Ragas AM; Russel FG; Scheepers PT
Environ Int; 2015 Jan; 74():231-9. PubMed ID: 25454240
[TBL] [Abstract][Full Text] [Related]
8. Dermal, oral, and inhalation pharmacokinetics of methyl tertiary butyl ether (MTBE) in human volunteers.
Prah J; Ashley D; Blount B; Case M; Leavens T; Pleil J; Cardinali F
Toxicol Sci; 2004 Feb; 77(2):195-205. PubMed ID: 14600279
[TBL] [Abstract][Full Text] [Related]
9. A physiologically based pharmacokinetic model of organophosphate dermal absorption.
van der Merwe D; Brooks JD; Gehring R; Baynes RE; Monteiro-Riviere NA; Riviere JE
Toxicol Sci; 2006 Jan; 89(1):188-204. PubMed ID: 16221965
[TBL] [Abstract][Full Text] [Related]
10. Percutaneous absorption studies of octamethylcyclotetrasiloxane using the human skin/nude mouse model.
Zareba G; Gelein R; Morrow PE; Utell MJ
Skin Pharmacol Appl Skin Physiol; 2002; 15(3):184-94. PubMed ID: 12077471
[TBL] [Abstract][Full Text] [Related]
11. Percutaneous absorption, biotransformation, and systemic disposition of parathion in vivo in swine. I. Comprehensive pharmacokinetic model.
Qiao GL; Williams PL; Riviere JE
Drug Metab Dispos; 1994; 22(3):459-71. PubMed ID: 8070325
[TBL] [Abstract][Full Text] [Related]
12. Development of an integrated multi-species and multi-dose route PBPK model for volatile methyl siloxanes - D4 and D5.
McMullin TS; Yang Y; Campbell J; Clewell HJ; Plotzke K; Andersen ME
Regul Toxicol Pharmacol; 2016 Feb; 74 Suppl():S1-13. PubMed ID: 26724268
[TBL] [Abstract][Full Text] [Related]
13. Percutaneous penetration and metabolism of 2-butoxyethanol.
Lockley DJ; Howes D; Williams FM
Arch Toxicol; 2004 Nov; 78(11):617-28. PubMed ID: 15455191
[TBL] [Abstract][Full Text] [Related]
14. A generic, cross-chemical predictive PBTK model with multiple entry routes running as application in MS Excel; design of the model and comparison of predictions with experimental results.
Jongeneelen FJ; Berge WF
Ann Occup Hyg; 2011 Oct; 55(8):841-64. PubMed ID: 21998005
[TBL] [Abstract][Full Text] [Related]
15. Estimation of dermal absorption using the exponential saturation model.
Thongsinthusak T; Ross JH; Saiz SG; Krieger RI
Regul Toxicol Pharmacol; 1999 Feb; 29(1):37-43. PubMed ID: 10051417
[TBL] [Abstract][Full Text] [Related]
16. Dermal absorption of arsenic from soils as measured in the rhesus monkey.
Lowney YW; Wester RC; Schoof RA; Cushing CA; Edwards M; Ruby MV
Toxicol Sci; 2007 Dec; 100(2):381-92. PubMed ID: 17872898
[TBL] [Abstract][Full Text] [Related]
17. Inhalation dosimetry modeling with decamethylcyclopentasiloxane in rats and humans.
Reddy MB; Dobrev ID; McNett DA; Tobin JM; Utell MJ; Morrow PE; Domoradzki JY; Plotzke KP; Andersen ME
Toxicol Sci; 2008 Oct; 105(2):275-85. PubMed ID: 18583370
[TBL] [Abstract][Full Text] [Related]
18. Approaches for evaluating the relevance of multiroute exposures in establishing guideline values for drinking water contaminants.
Krishnan K; Carrier R
J Environ Sci Health C Environ Carcinog Ecotoxicol Rev; 2008; 26(3):300-16. PubMed ID: 18781539
[TBL] [Abstract][Full Text] [Related]
19. A toxicokinetic model of malathion and its metabolites as a tool to assess human exposure and risk through measurements of urinary biomarkers.
Bouchard M; Gosselin NH; Brunet RC; Samuel O; Dumoulin MJ; Carrier G
Toxicol Sci; 2003 May; 73(1):182-94. PubMed ID: 12657741
[TBL] [Abstract][Full Text] [Related]
20. Evaporation of decamethylcyclopentasiloxane (D5) from selected cosmetic products: Implications for consumer exposure modeling.
Dudzina T; Garcia Hidalgo E; von Goetz N; Bogdal C; Hungerbuehler K
Environ Int; 2015 Nov; 84():55-63. PubMed ID: 26222996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
